Subsequent Events

12 Months Ended

Dec. 31, 2024

Subsequent Events

Subsequent Events

11. Subsequent Events

On January 29, 2025, the Company completed an acquisition of SeQure Dx Inc., a Delaware corporation (“SeQure”), a market leader of on-target and off-target editing assessment services for cell and gene therapies.  The Company paid a total initial consideration of $4,500 at closing in cash for the entire issued share capital of SeQure.  An additional amount, that will not exceed $2,500, may be paid in cash contingent consideration if SeQure exceeds certain revenue targets for the years ended December 31 2025 and 2026.